Chapter 70 GDP and GDP per capita


Chapter 70 GDP and GDP per capita

"Recently we have received a lot of complaints from 'aplastic patients', especially the 'Aplastic Patients Alliance' has put a lot of pressure on them, hoping to introduce it as soon as possible' ITG human myelopoietin'."

The speaker is a middle-aged white man with a Mediterranean hairstyle that is particularly eye-catching in the conference room.

“Not only 'ITG human genin', there are too many videos about China on Youtube and Twitter recently. Our medical system has also been subject to many complaints and attacks. If this continues, it is likely to cause Marches and strikes. "

After the words fell, there was silence in the conference room. Everyone knew that it was really urgent, and those patients and their families would really go to the streets to cause trouble.

After a while, the white man sitting in the middle frowned and said slowly:

"So, we must take action."

"I suggest that we can generate it with this 'ITG human body' Contact the Chinese manufacturers of Su' to discuss whether it can be introduced into the country. "

"This will at least alleviate public opinion on the Internet and calm more people attacking our medical system."

“I agree!”

"I agree too."

The white man's proposal was quickly approved by everyone, and the next question was who would talk.

Generally speaking, drugs introduced into foreign markets are reached by pharmaceutical companies through mutual communication. After all, this is a market-oriented commercial operation.

Soon, someone suggested:

“I think we can ask GlaxoSmithKline to come forward and talk to them.”

"GSK? Well, I think it's good too."

GSK is a global biopharmaceutical company based in the UK. Its business covers 75 countries and its business includes biopharmaceuticals and biovaccines. etc., is a truly international pharmaceutical giant.

Among them, the most well-known drugs are amoxicillin and HPV cervical cancer vaccine.

When the British National Health Center approached GlaxoSmithKline, GlaxoSmithKline agreed.

Actually,

They had noticed this drug called "ITG Human Myelopoietin" a few days ago and were already collecting information from Qingshan Pharmaceutical.

Just three days later, Lucas, the general manager in charge of sales in the Asia-Pacific region, flew to Qingshan Pharmaceutical.

With the previous cooperation with Fuxing Pharmaceutical, when he learned that Lucas, the head of Asia Pacific of "GSK", would come to Qingshan Pharmaceutical in person, Zhang Yang was not resistant and was even a little interested.

As we all know,

biopharmaceuticals, new energy vehicles, and electronic products have completely different sales channels and sales methods.

For new energy vehicles and mobile phones, such as Tesla and Xiaomi, they can set up their own direct-sales stores, and manufacturers can directly face customers.

However, the threshold for biopharmaceuticals is too high, and most drugs can only be sold through hospitals. Therefore, "drugs entering hospitals" has become a road that every pharmaceutical company in every market cannot avoid.

In addition, various national food and drug administrations have different marketing standards for drugs. If they want to be marketed, they must redo clinical trials locally. How many pharmaceutical companies have the energy?

For example, Pfizer of the United States can only choose to cooperate with Huaxia Pharmaceutical when it enters the country. Hengrui Pharmaceutical sells new drugs in the United States and also cooperates with domestic pharmaceutical companies in the United States. This is the consensus of the entire biopharmaceutical industry.

So,

If we can really cooperate with a large British pharmaceutical company like "GSK", it would be a good choice for Qingshan Pharmaceutical.

In the future, we can even use GlaxoSmithKline to bring other drugs into the UK more smoothly.

"Sit down, Mr. Lucas." Zhang Yang greeted warmly with a smile on his face.

"Thank you! Zhang, I didn't expect you to be so young."

Lucas praised him from the bottom of his heart and then quickly got to the point.

"Zhang, your 'ITG human myelopoietin' has been very popular in our country recently, so I hope to have a good talk with you this time. We want to introduce this drug to the UK."

Zhang Yang nodded slightly, indicating for Lucas to continue.

Seeing this, Lucas sat up straight and spread his hands:

"I'll just show off my cards. I've prepared two ways this time. The first one is for us to sign 'License Agreement', also known as 'license-out'; after signing, we will give you a one-time licensing fee, about...3 billion pounds."

"The second...that is traditional. Agency model, we act as an agent to purchase drugs from you, and then make a profit in the middle.”

"The second one."

Zhang Yang decisively chose the second one. The first "license-out" model is a very common cross-border transaction model in the pharmaceutical industry in the past decade.

To put it simply, it is a one-time sale of the permanent commercial development rights in a certain market. The subsequent production, sales, and commercialization of this drug in the region will have nothing to do with you. .

This is very attractive to some small pharmaceutical companies that are in urgent need of realizing their results, but Zhang Yang does not want to lose control of the "ITG Generator" in the British market.

Lucas shrugged. Of course he wanted to sign the first "license-out".

There are approximately 400,000 patients with aplastic anemia in the British Isles. Even if 300,000 people receive treatment and each injection costs 3,000 pounds, the total sales will be 9 billion pounds.

And this is only for now. There will undoubtedly be new patients with aplastic anemia every year in the future. This is obviously a sure-profit deal.

However,

Lucas breathed out softly and looked at Zhang Yang helplessly.

"Okay, Zhang, let's talk about the purchase price."

"As far as I know, the price of Fuxing Pharmaceutical authorized by your company in Southeast Asia is 4,000 US dollars. Their purchase price should be Between 2,500 and 3,000 US dollars.”

“I don’t expect to be cheaper than them. What do you think of 2,500 US dollars?”

2,500 US dollars?

Zhang Yang smiled and suddenly stretched out five fingers.

"Let me give you a price, 5,000 US dollars each."

What? !

5000...USD? !

After the words fell, Lucas’ eyes widened in disbelief, and he hurriedly said:

“Zhang, your selling price in Southeast Asia is only 4,000 US dollars, how can our purchase price be so high? So expensive!”

Zhang Yang slowly shook his head and said:

"Mr. Lucas, as you know, the pricing of a drug is often determined based on the economic conditions of the local market."

"Correspondingly Compared with the Philippines, Vietnam, and Thailand, you are a developed country, and your total GDP is several times theirs, so it is normal for the price to be higher.”

“Are you right?”

Lucas was stunned for a moment. What Zhang Yang said was true in the industry.

Generally speaking, innovative drugs in developed countries are indeed more expensive.

He nodded slightly, and suddenly felt something was wrong.

The next second, he suddenly reacted!

When collecting information before, the selling price of Qingshan Pharmaceutical in China was only 2,800 yuan!

If compared with GDP, China’s GDP is the second in the world!

He said anxiously:

"Mr. Zhang, I disagree with your GDP statement!"

"China's current total GPD is already the second in the world, and it is a truly developed country!"

"The selling price of Kegui Company in China is only 2,800 yuan..."

Before he finished speaking, Zhang Yang suddenly waved his hand:

"The Chinese market cannot be calculated like this. The Chinese market is based on per capita GDP."

"Per capita GDP?"

"Well, China's per capita GDP is only US$12,000. It is obviously a developing country. Your British GDP per capita is as high as $50,000!”

“So, $5,000 a pop is no problem.”

(End of this chapter)

Previous Details Next